Skip to main content

Table 4 Characteristics associated with 28-day mortality among patients who received intravenous PMB

From: Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study

Parameter Value for: P
Survivors (n = 60) Nonsurvivors (n = 40)
Age, y, mean ± SD 54.65 ± 16.23 57.8 ± 18.45 0.370
Female, n (%) 47 (78.3) 32 (80.0) 0.840
WBC, × 109/L, median (IQR) 14.28 (10.58, 20.44) 13.84 (9.55, 19.65) 0.359
PLT, × 109/L, mean ± SD 131.37 ± 101.96 71.15 ± 66.27 0.001
PCT, ng/ml, median (IQR) 2.30 (0.70, 10.07) 5.00 (1.97, 15.93) 0.062
CRP, ug/l, median (IQR) 100.15 (50.70, 174.33) 119.96 (79.58, 186.0) 0.624
SOFA, mean ± SD 6.77 ± 4.07 9.25 ± 4.25 0.004
APACHE II, mean ± SD 16.17 ± 7.80 19.78 ± 6.80 0.016
Mechanical ventilation, n (%) 21 (35.0) 30 (75.0) < 0.001
Septic shock, n (%) 17 (28.3) 32 (80.0) < 0.001
Hospitalization before intravenous PMB, days, median (IQR) 12.00 (5.25, 20.75) 11.50 (3.25, 21.00) 0.882
ICU stay before intravenous PMB, days, median (IQR) 9.00 (3.00, 15.00) 5.00 (1.00, 14.00) 0.156
Treatment duration, days, median (IQR) 11.00 (9.00, 13.00) 10.00 (8.25, 13.75) 0.697
Concomitant antibiotic therapy, n (%) 0.844
 PMB + Carbapenem 19 (31.67) 11 (27.5)  
 PMB + Carbapenem + Tigecycline 16 (26.67) 10 (25)  
 PMB + Tigecycline 6 (10) 5 (12.5)  
 PMB + Cephalosporin 4 (6.67) 5 (12.5)  
 PMB + Carbapenem + Cephalosporin 4 (6.67) 4 (10)  
 Others 11 (18.33) 5 (12.5)  
Daily dose of PMB, mg/day, n (%) 0.425
 100 35 (58.33) 18 (45)  
 150 9 (15) 8 (20)  
 200 16 (26.67) 14 (35)  
Identify microorganisms, n (%) 52 (86.67) 33 (82.5) 0.580
KP, n (%) 32 (53.3) 16 (40.0) 0.191
AB, n (%) 19 (31.7) 14 (35) 0.728
Multisite infection, n (%) 20 (33. 3) 15 (37.5) 0.669
Pulmonary infection, n (%) 35 (58.3) 29 (72.5) 0.217
BSI, n (%) 26 (43.3) 14 (35.0) 0.405
Chronic medical conditions, n (%) 45 (75.0) 32 (80.0) 0.734
Nephrotoxicity, n (%) 13 (21.7) 13 (32.5) 0.251
Adverse reactions, n (%) 8 (13.3) 8 (20.0) 0.373
  1. Categorical variables are presented as numbers (%), and continuous variables are presented as mean ± SD or interquartile ranges [IQR]
  2. WBC: white blood cell; PLT: platelet count; PCT: procalcitonin; CRP: C-reactive protein; SOFA: Sequential Organ Failure Assessment; APACHEII: Acute Physiology and Chronic Health Evaluation II; PMB: polymyxin B; ICU: intensive care unit; KP: Klebsiella pneumoniae; AB: Acinetobacter baumannii; BSI: Bloodstream Infection; SD: standard deviation